SMMC-7721 cells seeded in 24-well plates were cultured in humidified incubator for 12h. Cells were transiently transfected with vectors or siRNAs 12h later according to the protocol. EdU Cell Proliferation Assay Kit (Ribobio, Wuhan, China) were used to detect the cellular proliferation after 48h. Briefly, fixed SMMC-7721 cells were stained with EdU following the recommendations after incubation with 50μM EdU.
The ratio of EdU positive cells to total Hoechst positive cells was regarded as EdU incorporation rate.
miRNA transfection
The miR-22-3p mimic and miR-22-3p inhibitor were obtained from Shanghai Genepharma Company, China. The miRNA mimics or inhibitor were introduced into HCC cells using Lipofectamine RNAiMAX Transfection Reagent (Invitrogen) following the manufacturer's instruction. After incubation for 24-48 hours, cells were ready for the following assays.
Luciferase reporter assays
SMMC-7721 cells were cultured in 24-well plates and co-transfected with 40ng plasmids containing wild type HMGB1 3'-UTR sequences (termed psiCHECK-wt-HMGB1) or plasmids containing mutant HMGB1 3'-UTR sequences (termed psiCHECK-mut-HMGB1) and 20 pmol miR-22-3p mimic or negative control.
Luciferase activities of both firefly and Renilla were examined using the Dual-Luciferase® Reporter Assay System ((Promega) 48 hours later.
RNA interference
Small interfering RNAs were used in the current study to silence human MIR22HG gene expression. All target sequences for MIR22HG were synthesized by Genepharma Company and listed in Supplementary Table 6 . Lipofectamine RNAiMAX Transfection Reagent (Invitrogen) was used to perform transfection assays.
In situ hybridization (ISH)
ISH was carried out with the ISH Kit (Boster Bio-Engineering Company, Wuhan, China) to explore the expression of MIR22HG in HCC tissue and matched non-tumor tissues. Two pathologists who blinded to the clinical parameters reviewed and scored the ISH-staining regions for MIR22HG. The staining intensity was scored as follows: 0 (negative), 1 (weak), 2 (medium), 3 (strong). The score of staining extent was as follows: 0 (10%), 1 (1%-25%), 2 (26%-50%), 3 (51%-75%), and 4(76%-100%). The total score for MIR22HG was calculated based on the intensity and extent scores, ranging from 0 to 7. A total score ≥4 was defined as belonging in the high-expression group.
Immunohistochemistry (IHC)
IHC staining was performed to determine the expression of Ki-67 and HMGB1 in tumor tissues from subcutaneous xenograft model using Dako Envision System (Dako, Carpinteria, CA, USA) according to the manufacturer's recommended protocol. The tumor tissues were fixed with 10% formalin, embedded in paraffin, and then sectioned 4 μm in thickness. After baking at 65°C for 2 hours, sections were deparaffinized and rehydrated. Sections were submerged in sodium citrate buffer (pH 6.0) for antigen retrieval. After incubation with 0.3% H2O2 for 15 min to block the endogenous peroxidase, the sections were incubated with antibody for Ki-67 or HMGB1 overnight at 4°C. Sections were incubated with peroxidase labeled polymer conjugated to a secondary antibody at room temperature for 50 minutes after washing. Finally, diaminobenzidine (DAB) was used for color reactions.
Western blot
Total protein was extracted using RIPA buffer (Cell signaling Technology, Boston, MA, USA). The protein lysates were separated on a 12% SDS-polyacrylamide gel, and transferred onto polyvinylidene fluoride (Millipore, Bedford, MA, USA) membranes. After blocking with 5% BSA for 1 hour at room temperature, the membranes were incubated with primary antibodies overnight at 4°C. After washing, the membranes were incubated with the corresponding secondary antibodies conjugated to horseradish peroxidase. The membrane signals were detected using commercial ECL kit (Pierce, Rockford, IL, USA). 
Supplementary Tables
Supplementary Table 1 Clinicopathological characteristics of 52 HCC patients (52-patient cohort) Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer. *The values had statistically significant differences.
Supplementary Table S4
Overlapping genes predicted by miRanda and picTar miRNA GeneName has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR- 22-3p   JARID2  PTPN1  CTSC  COPS7B  ELOVL6  IKZF4  GALNT3  SEMA6D  SIRT1  BIN1  CDKN1A  PIP4K2B  EDC3  SMG7  CALM3  STYX  CAMK2N1  MXD1  HOXA4  KDM3A  ZBTB39  PRPF38A  BCL9  EP300  PURB  FRAT2  IPO7  LRRC16A  NFYA  ERBB3  EMILIN3  TRUB1  FAM96A  BATF3  C15orf29 has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR- 22-3p   NCOA1  MAPK14  SRF  MYCBP  FBXO45  CD147  KDM6B  PHF8  ERGIC2  SV2A  NET1  DPF2  LRP12  BTBD10  WASF1  NR3C1  CTDSPL2  RTN3  UNK  SATB2  PPP1R15B  CCDC47  DPYSL3  STK39  FBXL19  MTF2  TIAM1  WRNIP1  BTG1  NRAS  SLC2A1  LRRC1  HERPUD2  FBXW7  LIN7C  ATXN7  UBE2K  HSPG2  CENPV  EPC1 LGALS1
has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR- 22-3p   STAG2  CYTH3  NAA20  DPY30  STX4  HMGB1  ITGB3BP  EFNA5  AKT3  MAT2A  CPEB1  GNB4  ZNRF2  CLDND1  RAB5B  HNRNPUL2  PDIK1L  MSL2  SP1  TCF7L2  PLCXD3  POGK  CHD7  DNM3 has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR- 22-3p   TP53INP1  FOXP1  C6orf62  NDEL1  MAX  SNRK  PLAGL2  FOSL1  RNF38  ETS2  FAM49B  RSBN1  TGFBR1  MACROD2  MAP2K4  C17orf58  ARFIP2 has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p has-miR-22-3p
Supplementary Table S5
Primer sequence used in this study 
